These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 8053389)
1. Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone. Reginster JY; Treves R; Renier JC; Amor B; Sany J; Ethgen D; Picot C; Franchimont P J Bone Miner Res; 1994 May; 9(5):615-9. PubMed ID: 8053389 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study. Reginster JY; Colson F; Morlock G; Combe B; Ethgen D; Geusens P Arthritis Rheum; 1992 Aug; 35(8):967-74. PubMed ID: 1642662 [TBL] [Abstract][Full Text] [Related]
3. [Factors that determine intensity of response to treatment with tiludronate in Paget's disease]. Morales Piga A; Abraira Santos V; Rey Rey JS; de Abajo Iglesias F Med Clin (Barc); 1998 Feb; 110(7):254-8. PubMed ID: 9562949 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and bioequivalence of two oral formulations of tiludronate in the treatment of Paget's disease of bone. Morales-Piga A; Del Pino J; Rapado A; Diaz-Curiel M; Pallares M; Gonzalez-Macias J Clin Ther; 1997; 19(5):963-74. PubMed ID: 9385484 [TBL] [Abstract][Full Text] [Related]
6. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907 [TBL] [Abstract][Full Text] [Related]
7. (Chloro-4 phenyl) thiomethylene biphosphonate in Paget's bone disease. Reginster JY; Deroisy R; Lecart MP; Franchimont P Acta Belg Med Phys; 1989; 12(2):47-52. PubMed ID: 2603591 [TBL] [Abstract][Full Text] [Related]
8. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Roux C; Gennari C; Farrerons J; Devogelaer JP; Mulder H; Kruse HP; Picot C; Titeux L; Reginster JY; Dougados M Arthritis Rheum; 1995 Jun; 38(6):851-8. PubMed ID: 7779130 [TBL] [Abstract][Full Text] [Related]
9. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone. Chakravarty K; Merry P; Scott DG J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320 [TBL] [Abstract][Full Text] [Related]
10. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate. Chapuy MC; Charhon SA; Meunier PJ Metab Bone Dis Relat Res; 1983; 4(6):325-8. PubMed ID: 6229683 [TBL] [Abstract][Full Text] [Related]
11. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177 [TBL] [Abstract][Full Text] [Related]
12. Determinants of remission of Paget's disease of bone. Patel S; Stone MD; Coupland C; Hosking DJ J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048 [TBL] [Abstract][Full Text] [Related]
13. The effects of intravenous alendronate in Paget's disease of bone. O'Doherty DP; McCloskey EV; Vasikaran S; Khan S; Kanis JA J Bone Miner Res; 1995 Jul; 10(7):1094-100. PubMed ID: 7484285 [TBL] [Abstract][Full Text] [Related]
14. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate. de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976 [TBL] [Abstract][Full Text] [Related]
15. Aminohexane diphosphonate in the treatment of Paget's disease of bone. Atkins RM; Yates AJ; Gray RE; Urwin GH; Hamdy NA; Beneton MN; Rosini S; Kanis JA J Bone Miner Res; 1987 Aug; 2(4):273-9. PubMed ID: 3455614 [TBL] [Abstract][Full Text] [Related]
16. The methodology of clinical trials of oral tiludronate in Paget's disease of bone. Roux C Bone; 1995 Nov; 17(5 Suppl):497S-499S. PubMed ID: 8573426 [TBL] [Abstract][Full Text] [Related]
17. Tiludronate therapy for Paget's disease of bone. McClung MR; Tou CK; Goldstein NH; Picot C Bone; 1995 Nov; 17(5 Suppl):493S-496S. PubMed ID: 8573425 [TBL] [Abstract][Full Text] [Related]
18. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy. Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143 [TBL] [Abstract][Full Text] [Related]
19. Paget's disease of bone treated with a five day course of oral tiludronate. Reginster JY; Lecart MP; Deroisy R; Ethgen D; Zegels B; Franchimont P Ann Rheum Dis; 1993 Jan; 52(1):54-7. PubMed ID: 8427515 [TBL] [Abstract][Full Text] [Related]
20. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg. Abelson A Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]